After the WHO published data highlighting a concerning level of antibiotic resistance in strains of gonorrhoea, take a closer look at the three antibiotics currently in clinical trials for this pathogen.
The WHO has reported increasing drug resistance in gonorrhoea, with some cases untreatable by current antibiotics, and stated that new drugs are urgently required.
Researchers have discovered that the malaria parasite actively adapts to host calorie intake, identifying a nutrient-sensing enzyme that modulates the pathogen’s replication rate and virulence.
Researchers have developed a potential new treatment strategy for gonorrhoea that targets the enzyme needed for the bacterium to respire anaerobically in its oxygen-poor biofilm environment.
Researchers have discovered sequence-specific interactions between hepatitis B proteins and pre-genome RNA that may play a crucial role in nucleocapsid assembly. This could be targeted in future drug development.
Researchers have reported a small-molecule inhibitor of Candida albican protein Bdf1 and demonstrated the compound yields decreased fungal viability, suggesting a possible future antifungal.
As part of the authors ongoing research efforts dedicated to the discovery of novel cruzain inhibitors, a series of benzimidazole derivatives was used to develop predictive 2D and 3D quantitative structure–activity relationship (QSAR) models.
Improved therapeutic strategies are in urgent need for better control and eradication of tuberculosis. In this editorial, the authors evaluate interleukin-37 as a new molecular target for the therapy of tuberculosis.
In this exclusive piece the authors discuss the choice of peptide antigen, delivery system/adjuvant and delivery route as key factors in the development of an effective human vaccine against group A Streptococcus.
Resistance to β-lactams is an increasing problem. This review outlines various approaches taken to discover MBL inhibitors, with an emphasis on the different chemical classes of inhibitors.
